Goldman Sachs’s LifeMD LFMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.66M Buy
459,803
+197,357
+75% +$683K ﹤0.01% 4691
2025
Q4
$895K Sell
262,446
-27,989
-10% -$136K ﹤0.01% 5219
2025
Q3
$1.97M Buy
290,435
+95,674
+49% +$790K ﹤0.01% 4490
2025
Q2
$2.65M Buy
194,761
+29,357
+18% +$277K ﹤0.01% 3958
2025
Q1
$900K Sell
165,404
-244,145
-60% -$1.39M ﹤0.01% 4764
2024
Q4
$2.03M Buy
409,549
+25,139
+7% +$132K ﹤0.01% 4271
2024
Q3
$2.01M Buy
384,410
+267,966
+230% +$1.54M ﹤0.01% 4151
2024
Q2
$799K Sell
116,444
-257,703
-69% -$2.36M ﹤0.01% 4549
2024
Q1
$3.85M Buy
374,147
+357,651
+2,168% +$2.64M ﹤0.01% 3336
2023
Q4
$137K Buy
+16,496
New +$119K ﹤0.01% 5241
2022
Q2
Sell
-15,754
Closed -$56K 6598
2022
Q1
$56K Sell
15,754
-7,035
-31% -$25K ﹤0.01% 6244
2021
Q4
$88K Buy
+22,789
New +$108K ﹤0.01% 6168
2021
Q3
Sell
-48,074
Closed -$566K 6383
2021
Q2
$566K Buy
48,074
+20,612
+75% +$237K ﹤0.01% 5140
2021
Q1
$434K Buy
+27,462
New +$494K ﹤0.01% 5222

Other funds holding LFMD

Goldman Sachs's LFMD Position: Q1 2026 in Review

Goldman Sachs increased its LifeMD (LFMD) stake by 75% in Q1 2026, buying an estimated $683K and bringing the position to 459,803 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4691.

Goldman Sachs first reported a position in LFMD in Q1 2021 and has held it in 14 quarters since. The position peaked at $3.85M in Q1 2024. 102 funds tracked by Wall St. Rank hold LFMD as of Q1 2026.

  • Goldman Sachs held 459,803 shares of LifeMD worth $1.66M as of Q1 2026.
  • Goldman Sachs bought 197,357 LifeMD shares in Q1 2026, an estimated $683K.
  • LifeMD made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4691 holding.
  • Goldman Sachs first reported a position in LifeMD in Q1 2021 and has held it in 14 quarters since.
  • Goldman Sachs's LifeMD position peaked at $3.85M in Q1 2024.
  • 102 funds tracked by Wall St. Rank held LifeMD as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.